beat · 32 stories
The trigger is a viral protease, an enzyme the virus uses to assemble itself, that also cuts a bacterial sensor and flips on CBASS, one of the most common antiviral defenses.
A study in the journal *Brain* validates a long-studied inflammation target in real human brain tissue, opening a path to repurpose existing drug candidates against TBI and Alzheimer's.
A Cornell team found BC200, a gene that helps neurons build proteins, never stopped moving through DNA, and two copies of it ended up inside a human poxvirus.
The framework ranked prompt-defined competence on synthetic MI (motivational interviewing) and CBT (cognitive behavioral therapy) sessions. The open test is real trainees and item-level fidelity benchmarks.
The 31-valent shot met its primary endpoints, with strain coverage well beyond Pfizer's Prevnar 20 and Merck's Capvaxive, the two current adult pneumonia vaccines, but two more trials still gate an FDA filing.
Nolla Health will assess Utah patients for mild-to-moderate acne and write a low-risk prescription, with a clinician signing off in the first phase and a path to unsupervised prescribing under the state AI sandbox.
Merck and Moderna's vaccine improved recurrence-free survival in a 1,137-patient Phase 3 melanoma trial. A BioNTech halt in colorectal cancer shows the platform being matched, cancer by cancer.
The Small paper reports an antibody-free way to isolate extracellular vesicles — the cell's natural 'shipping parcels' — and a light-triggered switch that releases cargo inside target cells, tested in primary human liver cells.
PONG 2.0 reads immune genetics from cheap DNA-chip data already in biobank samples with comparable accuracy across African, South Asian, East Asian, European, and Admixed American samples.
Aptamers, short engineered DNA strands that grab a specific target, can now be profiled at 11,792 candidates per run, with Delta and Omicron binders pulled out in the same screen.
Frozen-section pathology, the quick lab slice of a tumor in the OR, averaged 36.3 minutes; a femtosecond, ultrashort-pulse laser plus a deep-learning model finished in 5.4 in a 144-patient Shanghai trial.
A new review says the chemistry of light-controlled pain medicine has matured, but the engineering to get the molecules to the right tissue at the right time is the harder problem.